Scale -

  • Revenue is 8280 Rs Cr; Continuous Growth over 3 years
  • Ebitda is 1326 Rs Cr; Continuous Growth over 3 years
  • PBT is 86.4 Rs Cr; Annual Decline is -37 %; in Bottom Quartile
  • PAT is 398 Rs Cr; Annual Decline is -52 %
  • Quarterly Profit is 56.4 Rs Cr; in Bottom Quartile

Profitability -

  • PAT Margin is 4.8 %; Annual Decline is -58 %; in Bottom Quartile; 5 Year CAGR is -9 %
  • PBDIT Margin is 16.01 %; in Bottom Quartile
  • Quarterly Ebitda Margin is 11 %; in Bottom Quartile
  • Quarterly Profit margin is 3 %; in Bottom Quartile

Return -

  • Asset Turnover is 59 %; 5 Year CAGR is 133 %
  • ROA is 2.56 %; Annual Decline is -61 %; in Bottom Quartile
  • ROE is 5.61 %; Annual Decline is -58 %; in Bottom Quartile
  • ROCE is 6.81 %; in Bottom Quartile

Efficiency -

  • Inventory Turnover Ratio is 7.01; Continuous Growth over 3 years; in Top Quartile
  • Operating cash flow is 1227 Rs Cr; Continuous Growth over 3 years
  • Current Ratio is 1.62; Continuous Decline over 3 years; in Bottom Quartile

Solvancy -

  • Long term Debt is 2972 Rs Cr; Annual Growth is 38 %; in Top Quartile
  • Total Debt is 3220 Rs Cr; Annual Growth is 32 %; in Top Quartile
  • Contingent Liabilities is 1630 Rs Cr; Annual Growth is 34 %; in Top Quartile
  • Debt/Equity is 0.45; in Top Quartile

Quality -

  • Operating cashflow/PAT is 308 %; Annual Growth is 141 %; in Top Quartile
  • Exceptional Items/PBT is -10 %; Annual Decline is -126 %; in Bottom Quartile
  • Change in Inventories/Total Expenses is 0 %; Annual Decline is -73 %; Continuous Decline over 3 years; in Top Quartile
  • Other Expenses/Total Expenses is 22 %; Continuous Decline over 3 years; in Bottom Quartile
  • Operating cashflow/ebitda is 93 %; in Top Quartile
  • Current Tax/PAT is 40 %; Annual Growth is 59 %; in Top Quartile

Quarterly Results- overall

Annual Results- Scale

Annual Results- Liquidity

Annual Results- Profitability/Return

Annual Results- Valuation

External Ecosystem

Sector
Major Subsidiaries/Associates
Key Clients

Products

Products
Product details

Operations

Capacity/ Production
Key Facilities
Key Certifications
Raw materials
Recent News
Jubilant Pharmova Limited Estimates – NSE:JUBLPHARMA
Read More
  • Past/current
Jubilant Pharmova (NSEI:JUBLPHARMA)
Read More
  • Past/current
Jubilant Pharmova eyes $150 million through rupee debt sale, bankers say
Read More
  • Past/current
Jubilant Pharmova JUBLPHARMA Shareholder Notice Oct 2026
Read More
  • Past/current
Jubilant Pharmova seeks shareholder nod for ?2,500 crore NCD issuance
Read More
  • Past/current
Abakkus Buys Rs 101 Crore More in Jubilant Pharmova Shares
Read More
  • Past/current
Briefs: Sun Pharma, Jubilant Pharmova and Fortis Healthcare
Read More
  • Past/current
Jubilant Pharmova: Block Deal and NCD Fundraising Plan
Read More
  • Past/current
Abakkus buys additional Rs 101 crore worth of Jubilant Pharmova shares; Qualcomm exits Shadowfax
Read More
  • Past/current
Jubilant Pharmova block deal: Quant Mutual Fund offloads Rs 190 crore stake amid Rs 800 crore fundraising
Read More
  • Past/current
Jubilant Pharmova board approves ?800 crore NCD issuance via private placement
Read More
  • Past/current
Jubilant Pharmova Board Approves Rs 800 Cr NCD Issue
Read More
  • Past/current
Jubilant Pharmova: ??? ????? ???? ??????? ???? ?????, **?800 ????**?? NCD ??????? ??????
Read More
  • Past/current
Jubilant Draximage Invests CAD 94.5 Mn in Canada Facility, to Double RUBY-FILL Capacity
Read More
  • Past/current
Jubilant Pharmova radiopharma unit to invest CAD 94.5 million to double RUBY-FILL production
Read More
  • Past/current
Jubilant's Radiopharma business announces investment of CAD 94.5 million to double production capacity of its flagship product, RUBY-FILL
Read More
  • Past/current